Gilteritinib Improves Survival in AML with FLT3 Mutations - Cancer Currents Blog National Cancer Institute sent this bulletin at 11/27/2019 12:22 PM EST Having trouble viewing this email? View it as a Web page. You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below. Gilteritinib Improves Survival in AML with FLT3 Mutations 11/27/2019 People with relapsed or refractory acute myeloid leukemia (AML) with FLT3 gene mutations treated with gilteritinib had improved survival, higher rates of remission, and fewer side effects than those treated with chemotherapy, a recent trial found.
